1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
Manzo Pharmaceuticals, Inc.

Manzo Pharmaceuticals, Inc.

MNZO
Manzo Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
115,952.00Market Cap
2003 Y
2004 Y
Revenue per Share
0.93
0.89
Basic EPS, GAAP
-1.23
-1.2
Free Cash Flow per Basic Share
-0.49
-0.32
Dividend per Share
- -
- -
Book Value per Share
-8.44
-9.04
Tangible Book Value per Share
-5.73
-6.49
Basic Weighted Avg Shares
3
3
Sales/Revenue/Turnover
3
3
Operating Margin (%)
-108.14
-104.16
Depreciation Expense
- -
- -
Net Income, GAAP
-4
-4
Effective Tax Rate (%)
- -
- -
Profit Margin (%)
-131.63
-135.2
Working Capital
-22
-24
LT Debt
- -
- -
Total Equity
-18
-23
Return on Invested Capital (%)
- -
- -
Return on Capital (%)
- -
- -
Return on Common Equity (%)
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
21.88%
Free Cash Flow
- -
- -
-29.96%
Net Income, GAAP
- -
- -
4.99%
Sales/Revenue/Turnover
- -
- -
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
3
2004
- -
- -
- -
- -
3
2005
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
-1.23
2004
-0.29
- -
- -
- -
-1.2
2005
-0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2003
- -
- -
- -
- -
- -
2004
- -
- -
- -
- -
- -
2005
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Kenneth Manzo
Full Time Employees
12
Sector
Financial Services
Industry
Shell Companies
Address
PO Box 107 Milford PA United States of America 18337
IPO Date
Dec 31, 1998
CIK
0001119949
Website
lactofreedom.com
Similar Companies
EVe Mobility Acquisition Corp (EVE)
Jaguar Global Growth Corporation I (JGGC)
Bowen Acquisition Corp (BOWNR)
AxonPrime Infrastructure Acquisition Corporation (APMI)
Yorkville Acquisition Corp. Wt (MCGAW)
Hennessy Capital Investment Corp. VI (HCVIU)
Business
Manzo Pharmaceuticals, Inc. Manzo Pharmaceuticals, Inc. (MNZO), a specialty pharmaceutical company incorporated in 1980 and headquartered in Milford, Pennsylvania, engages in the research, development, testing, and commercialization of patented and non-patented probiotic and natural remedy solutions targeting digestive health issues; its primary product is Lacto-Freedom, a patented probiotic formulation featuring L. acidophilus MPH734 that aids in the digestion of lactose-containing dairy foods for individuals with lactose intolerance by preventing gas, bloating, diarrhea, and cramps following a seven-day regimen with effects reported to last up to six months; the company also develops a natural remedy for colic in babies. All products are manufactured in the USA, with Lacto-Freedom co-developed by founder and CEO Kenneth Manzo, a licensed pharmacist in New York, New Jersey, and Pennsylvania, in collaboration with Celprogen, Inc., a California-based biotech firm. The company, formerly known as Fortune Oil & Gas, Inc., changed its name to Manzo Pharmaceuticals, Inc. in September 2014 to reflect its strategic shift from oil and gas to pharmaceuticals, and it operates primarily in the United States with a small team of 12 employees focused on the healthcare sector's probiotics and infant care segments.